Tag: Oral
Genetic clues to tackle oral cancer among Indian women revealed
This investigation was specifically designed to uncover the biological underpinnings of the disproportionately aggressive, highly recurrent, and life-threatening forms of oral cancer that affect Indian women
Bharat Biotech’s oral cholera vaccine ‘Hillchol’ demonstrates success in phase III...
Hillchol will have a major impact in addressing the global shortage of cholera vaccines
Akums Drugs secures patent for room temperature stable oral suspension of...
This development offers a significant advance in addressing the storage and accessibility challenges associated with Hydroxyurea solution
Bharat Biotech launches HILLCHOL-the next generation oral cholera vaccine
Bharat Biotech's collaboration with MSD, Wellcome-Trust Hilleman Laboratories aims to address the critical shortage of OCVs
ERLYSIGN gets CDSCO approval for large-scale clinical trials for oral cancer...
The company also secures patents for Oral Cancer Detection Kit in India and the US
National Oral Health Task Force set up to enhance oral health...
The Task Force is aligned with the Global Oral Health Action Plan of WHO South-East Asia Regional committee
Zydus acquires UK based LiqMeds
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026 depending on achievement of certain agreed milestones towards acquisition of the LiqMeds Group of companies
COVCUR ensures oral hygiene in Covid appropriate behaviour
Mumbai based nanotech scientist develops world’s first nano-curcumin oral spray proven for prophylactic protection against Covid-19 causing corona viruses.......................
Premas Biotech & Oramed announce oral COVID-19 vaccine candidate that produces...
With triple antigen targeting, the vaccine is claimed to offer better protection against COVID-19 variants. While Oravax Medical Inc has been established to accelerate the vaccine’s path to market, clinical trials are expected to commence in Q2 2021......................
Zydus to begin Phase I trials of its inflammation drug, ZYIL1
Phase I trial will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in healthy human volunteers. Zydus has secured a Strong IP portfolio with multiple patents filed in all major countries.....................